Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ABT-578

Known as: ABT 578, ABT578 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
OBJECTIVES This study sought to report the final 5-year outcomes of the ENDEAVOR IV (A Randomized, Controlled Trial of the… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Review
2006
Review
2006
Drug-eluting stents have revolutionized the field of interventional cardiology and have provided a significant innovation for… Expand
Review
2006
Review
2006
Drug-eluting stents (DESs) have shown significant promise at reducing rates of restenosis and subsequent revascularization… Expand
2005
2005
Stent‐based delivery of the antiproliferative and immunosuppressive macrocyclic lactone sirolimus reduces neointimal formation… Expand
2005
2005
We report here a specific, automated LC/LC-MS/MS assay for the quantification of ABT-578 in human and rabbit blood and rabbit… Expand
2005
2005
AbstractObjective: ABT-578, a tetrazole analogue of sirolimus (rapamycin), possesses anti-restenosis activity. The aim of this… Expand
Review
2005
Review
2005
The introduction of drug-eluting stents (DES) to interventional cardiology practice has resulted in a significant improvement in… Expand
Review
2004
Review
2004
Abstract.ABT-578 is a new synthetic analog of rapamycin, designed to inhibit smooth muscle cell proliferation—a key contributor… Expand
  • figure 1
  • figure 2
2004
2004
We report here a quantitative method for the analysis of ABT-578 in human whole blood samples. Sample preparation was achieved by… Expand
2004
2004
Quantitative determination of drug concentrations in tissue samples can provide critical information for drug metabolism… Expand